

Q11: Which mechanistic endpoints should be incorporated in preclinical experiments to complement pain-related behavior assessment (e.g., should we do electrophysiology, DRG expression/proteomics etc) to define pain phenotypes/endotypes?

Ewan St. John Smith, Jason Ivanusic, Rik Lories, Victoria Chapman, Kelsey H. Collins, Niels Eijkelkamp, Rachel E. Miller, Emerson Krock

RESPONSE/RECOMMENDATION:

Researchers should incorporate endpoint evaluations to support a molecular, cellular, and behavioral understanding of OA pathology and pain. We do not prescribe a minimum number of endpoints, but endpoints that capture functional activity, such as electrophysiology, can be particularly informative; rigor should be defined by mechanistic relevance and internal consistency, not by the number of endpoints. Although structural changes do not necessarily denote pain, joint structure assessment is recommended to correlate structural and pain phenotypes.

LEVEL OF EVIDENCE:

Strong. Publishing mechanistic endpoint data to support behavioral observations has clear benefits, although animal behavior complexity means that no fixed number of analyses guarantees mechanistic insight. Given their role in the sensation of pain, researchers are encouraged to focus on sensory neuron function and associated central circuitry, but we note important roles of non-neuronal cells in modulating pain¹.

RATIONALE: Eligibility criteria:

PubMed searches (5th February 2026) for “osteoarthritis pain behavior AND rat” and “osteoarthritis pain behavior AND mouse” returned 446 and 259 results respectively, making full review of mechanistic endpoints infeasible. We therefore discuss commonly used methods and/or those enabling gain in strong mechanistic insight. We focus on mice and rats, the most used species in preclinical OA studies; separate questions address large animals (Q4) and companion animals (Q5). When reviewing mechanistic endpoints, there is also room for debate about the relevance of the animal model used to study OA vs. joint pain in general^{2,3}. We have considered endpoints that could be used to assess pain mechanisms in OA models, rather than excluding any method not routinely incorporated into OA research to date. Although endpoint analysis could restrict discussion to methods only used postmortem, we have also considered longitudinal methods. Our aim is not to provide an exhaustive inventory, but to highlight categories that offer clear interpretive value.

Mechanistic endpoints:

1) Structural assessment of joints: Histological scoring of cartilage damage is the gold standard^{4–7}, but cannot be conducted in live animals, which precludes studying acute to chronic pain transition in the same animal. MRI imaging⁸, μ CT, and dual energy X-ray absorptiometry are also often used to measure bone mineral content. Features of synovitis have also been shown to correlate with symptoms pre-clinically and clinically^{9–13}. However, structural joint damage and pain can also be uncoupled, with discordance notable in clinically meaningful subgroups, like people with obesity¹⁴. In addition to traditional immunostaining of sections, microscopy, spatial transcriptomics, and more sophisticated 3D visualization tools are actively being developed to provide further information on the innervation of the joint (see below)¹⁵.

2) Electrophysiology: measures sensory neuron excitability. In vivo electrophysiology includes: i) recording from knee and bone afferents, which in OA models show hyperactivity to torque and mechanical stimulation^{16–19}, and ii) recording from spinal cord dorsal horn neurons, which exhibit hypersensitivity indicative of central sensitization in OA models²⁰. In vitro dorsal root ganglia (DRG) sensory neuron recordings from OA rodents show enhanced voltage-gated ion channel activity^{21,22}. Retrograde tracing of knee afferents enables recording of neurons innervating the OA joint, which exhibit hyperexcitability aligned with pain-related behaviors^{23,24}. Thus, electrophysiology provides precise readouts of how neuronal activity changes as OA pain behavior changes, which can be combined with pharmacology and/or genetics to investigate specific molecular targets. Electrophysiology does however require bespoke equipment and specific training, which might limit feasibility of incorporation into experimental pipelines.

3) Ca^{2+} -imaging: measures neuronal activity via an action potential, Ca^{2+} flux through Ca^{2+} permeable ion channels, or intracellular Ca^{2+} mobilization via G protein-coupled receptors. Ca^{2+} -sensitive dyes and genetically encoded Ca^{2+} indicators enable higher throughput than electrophysiology, although automated electrophysiology of DRG neurons is feasible²⁵. Knee-innervating neurons of OA mice show increased TRPV1 responsiveness²³, correlating with the role of TRPV1⁺ neurons in rodent OA²⁶. Similarly, increased responsiveness to molecules elevated in the OA joint has been observed in DRG neurons isolated from OA animals and those same molecules induce knee hypersensitivity^{27–30}. In vivo Ca^{2+} -imaging of lumbar DRG demonstrates increased neuronal responsivity to mechanical paw/knee stimulation in OA³¹. Thus Ca^{2+} -imaging maps changes in neuronal activity to behaviors and represents a pragmatic balance between mechanistic insight and experimental scalability.

4) Multi-omic profiling of tissues: Western blot or immunohistochemistry are low-cost tools to identify single or few proteins of interest, but a variety of high-throughput, unbiased techniques, e.g. metabolomics, lipidomics, and RNA sequencing, can be leveraged to understand the multi-dimensional molecular changes in OA. Single cell datasets of human neurons³², synovium¹³ and infrapatellar fat pads³³ are available. Future directions include integrating cell- and tissue-datasets³⁴, including spatial -omics³⁵ to link cellular and tissue changes to pain behavior. In depth data analysis of omics data often requires specialized bioinformatic/computational knowledge, which may limit widespread adoption until the development of affordable, commercially available analysis programs.

5) Neuronal innervation: Subchondral bone, synovium and the joint capsule are innervated by sensory neurons^{36–45} and are likely targets for mechanism-based OA therapies. Most work has focused on soft tissue innervation because of ease of experimental access^{16,36,45–52}, but changes in subchondral bone^{53–56} innervation are increasingly recognized. Innovative methods, such as light-sheet microscopy, enable 3D visualization of these changes^{54,57–59}. Increased subchondral bone innervation correlates with OA symptoms in clinical and pre-clinical studies^{51,52,60}. Understanding the relationship between nerve structure and function changes across joint tissues will provide important mechanism-based insights into OA pain.

6) Neuroimmune interactions: Neuroimmune interactions in the DRG and spinal cord actively sustain OA pain independently of joint pathology, e.g. M1-like DRG macrophages accumulate and their depletion/reprogramming resolves persistent pain without affecting knee pathology, implicating immune cell state as a causal driver of pain^{61–65}. Tools such as spectral flow cytometry, immunohistochemistry, and 3D tissues-clearing/light-sheet imaging provide quantitative, spatial, and temporal resolution of these mechanisms in DRG and spinal cord, providing complementary mechanistic insight into OA pain mechanisms beyond neuronal endpoints.

7) Activity mapping and circuit-level plasticity markers: Immediate-early gene (c-Fos) and kinase activation (pERK) in the spinal dorsal horn map nociceptive drive and central sensitization. pERK is particularly dynamic (seconds–minutes) and closely linked to central sensitization mechanisms, whereas c-Fos reports integrated activation over tens of minutes. Increased dorsal horn c-Fos positive cells have been observed in OA models^{66–70}. Genetic activity tagging (e.g., TRAP/FosTRAP) can link circuit recruitment to behavior. Pain-associated neuropeptides released by primary afferents in the dorsal horn (e.g., CGRP, Substance P) are elevated in rodent models of OA^{71,72}, and reflect increased synaptic transmission⁷³. Functional brain imaging can also correlate circuitry changes with pain behaviors^{8,74–76}, but like other in vivo imaging approaches requires expensive, specialized equipment, which presents a barrier to most researchers being able to incorporate it into their studies as a routine mechanistic endpoint.

Conclusion

While no single mechanistic endpoint fully captures the complexity of OA pain, combining behavior with at least one functional neuronal readout and one joint tissue–level measure provides a robust and interpretable framework for mechanistic studies. Endpoint selection should remain driven by the specific biological question, technical feasibility, and translational intent.

References

1. Smith EstJ, Burton MD, Heegaard A-M, Stucky CL. 2025. Not Just Neurons: Pain Is Orchestrated in Partnership with Many Non-neuronal Cells. *J. Neurosci.* 45(46):e1309252025.
2. Alves-Simões M. 2022. Rodent models of knee osteoarthritis for pain research. *Osteoarthritis Cartilage* 30(6):802–814.
3. Malfait AM, Little CB, McDougall JJ. 2013. A commentary on modelling osteoarthritis pain in small animals. *Osteoarthritis Cartilage* 21(9):1316–1326.
4. Mankin HJ, Dorfman H, Lippiello L, Zarins A. 1971. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. *J Bone Joint Surg Am* 53(3):523–537.
5. Buckwalter JA, Mankin HJ, Grodzinsky AJ. 2005. Articular cartilage and osteoarthritis. *Instr Course Lect* 54:465–480.
6. Glasson SS, Blanchet TJ, Morris EA. 2007. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. *Osteo Cart* 15(9):1061–1069.
7. Gerwin N, Bendele AM, Glasson S, Carlson CS. 2010. The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the rat. *Osteoarthritis and Cartilage* 18:S24–S34.
8. Abaei M, Sagar DR, Stockley EG, et al. 2016. Neural correlates of hyperalgesia in the monosodium iodoacetate model of osteoarthritis pain. *Mol Pain* 12:1744806916642445.
9. Obeidat AM, Kim SY, Burt KG, et al. 2024. A standardized approach to evaluation and reporting of synovial histopathology in two surgically induced murine models of osteoarthritis. *Osteo Cart* :S1063458424012056.
10. Jackson MT, Moradi B, Zaki S, et al. 2014. Depletion of protease-activated receptor 2 but not protease-activated receptor 1 may confer protection against osteoarthritis in mice through extracartilaginous mechanisms. *Arthritis Rheumatol* 66(12):3337–3348.
11. Neogi T, Guermazi A, Roemer F, et al. 2016. Association of Joint Inflammation With Pain Sensitization in Knee Osteoarthritis: The Multicenter Osteoarthritis Study: MRI LESIONS AND SENSITIZATION IN KNEE OA. *Arth Rheum* 68(3):654–661.
12. Scanzello CR, Goldring SR. 2012. The role of synovitis in osteoarthritis pathogenesis. *Bone* 51(2):249–257.
13. Philpott HT, Birmingham TB, Blackler G, et al. 2025. Association of Synovial Innate Immune Exhaustion With Worse Pain in Knee Osteoarthritis. *Arthritis Rheumatol* 77(6):664–676.
14. Collins KH, Haugen IK, Neogi T, Guilak F. 2025. Osteoarthritis as a systemic disease. *Nat Rev Rheumatol* .
15. Cruz-Almeida Y, Mehta B, Haelterman NA, et al. 2024. Clinical and biobehavioral phenotypic assessments and data harmonization for the RE-JOIN research consortium: Recommendations for common data element selection. *Neurobiol Pain* 16:100163.
16. Schuelert N, McDougall JJ. 2006. Electrophysiological evidence that the vasoactive intestinal peptide receptor antagonist VIP6–28 reduces nociception in an animal model of osteoarthritis. *Osteoarthritis and Cartilage* 14(11):1155–1162.

17. Morgan M, Thai J, Nazemian V, et al. 2022. Changes to the activity and sensitivity of nerves innervating subchondral bone contribute to pain in late-stage osteoarthritis. *Pain* 163(2):390–402.
18. Morgan M, Nazemian V, Ooi LS, et al. 2023. Artemin sensitizes nociceptors that innervate the osteoarthritic joint to produce pain. *Osteoarthritis Cartilage* 31(10):1342–1352.
19. Morgan M, Nazemian V, Thai J, et al. 2024. BDNF sensitizes bone and joint afferent neurons at different stages of MIA-induced osteoarthritis. *Bone* 189:117260.
20. Rahman W, Bauer CS, Bannister K, et al. 2009. Descending Serotonergic Facilitation and the Antinociceptive Effects of Pregabalin in a Rat Model of Osteoarthritic Pain. *Mol Pain* 5:1744-8069-5–45.
21. Hestehave S, Allen HN, Gomez K, et al. 2025. Small molecule targeting NaV1.7 via inhibition of CRMP2-Ubc9 interaction reduces pain-related outcomes in a rodent osteoarthritic model. *Pain* 166(1):99–111.
22. Shin SM, Cai Y, Itson-Zoske B, et al. 2020. Enhanced T-type calcium channel 3.2 activity in sensory neurons contributes to neuropathic-like pain of monosodium iodoacetate-induced knee osteoarthritis. *Mol Pain* 16:1744806920963807.
23. Bohic M, Pattison LA, Jhumka ZA, et al. 2023. Mapping the neuroethological signatures of pain, analgesia, and recovery in mice. *Neuron* 111(18):2811-2830.e8.
24. Ai M, Hotham WE, Pattison LA, et al. 2023. Role of Human Mesenchymal Stem Cells and Derived Extracellular Vesicles in Reducing Sensory Neuron Hyperexcitability and Pain Behaviors in Murine Osteoarthritis. *Arth Rheum* 75(3):352–363.
25. Ghovanloo M-R, Tyagi S, Zhao P, et al. 2023. High-throughput combined voltage-clamp/current-clamp analysis of freshly isolated neurons. *Cell Reports Methods* 3(1):100385.
26. Haywood AR, Hathway GJ, Chapman V. 2018. Differential contributions of peripheral and central mechanisms to pain in a rodent model of osteoarthritis. *Sci Rep* 8(1):7122.
27. Miller RE, Tran PB, Das R, et al. 2012. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. *PNAS* 109(50):20602–20607.
28. Miller RE, Ishihara S, Tran PB, et al. 2018. An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. *JCI Insight* 3:e95704.
29. Ishihara S, Obeidat AM, Wokosin DL, et al. 2021. The role of intra-articular neuronal CCR2 receptors in knee joint pain associated with experimental osteoarthritis in mice. *AR&T* 23(1):103.
30. Miller RE, Belmadani A, Ishihara S, et al. 2015. Damage-associated molecular patterns generated in osteoarthritis directly excite murine nociceptive neurons through Toll-like receptor 4. *Arthritis Rheumatol* 67(11):2933–2943.
31. Miller RE, Kim YS, Tran PB, et al. 2018. Visualization of Peripheral Neuron Sensitization in a Surgical Mouse Model of Osteoarthritis by In Vivo Calcium Imaging. *Arth Rheum* 70(1):88–97.
32. Copits BA, Curatolo M, Dougherty PM, et al. 2025. Human pain neuroscience and the next generation of pain therapeutics. *Neuron* 113(9):1304–1306.
33. Peters H, Potla P, Rockel JS, et al. 2025. Cell and transcriptomic diversity of infrapatellar fat pad during knee osteoarthritis. *Ann Rheum Dis* 84(2):351–367.

34. Rai MF, Collins KH, Lang A, et al. 2024. Three decades of advancements in osteoarthritis research: insights from transcriptomic, proteomic, and metabolomic studies. *Osteoarthritis Cartilage* 32(4):385–397.
35. Collins KH, Lenz KL, Welhaven HD, et al. 2025. Adipose-derived leptin and complement factor D mediate osteoarthritis severity and pain. *Sci Adv* 11(17):eadt5915.
36. Kidd BL, Photiou A, Inglis JJ. 2004. The Role of Inflammatory Mediators on Nociception and Pain in Arthritis. In: Chadwick DJ, Goode J, editors. *Novartis Foundation Symposia*, 1st ed. Wiley. p 122–138 [cited 2026 Jan 6] Available from: <https://onlinelibrary.wiley.com/doi/10.1002/0470867639.ch9>.
37. McDougall JJ. 2006. Arthritis and pain. Neurogenic origin of joint pain. *Arthritis Res Ther* 8(6):220.
38. Ivanusic JJ, Beainil D, Hatchl RJ, et al. 2011. Peripheral *N*-methyl- *D*-aspartate receptors contribute to mechanical hypersensitivity in a rat model of inflammatory temporomandibular joint pain. *European Journal of Pain* 15(2):179–185.
39. Hatch RJ, Jennings EA, Ivanusic JJ. 2013. Peripheral hyperpolarization-activated cyclic nucleotide-gated channels contribute to inflammation-induced hypersensitivity of the rat temporomandibular joint. *European Journal of Pain* 17(7):972–982.
40. Krustev E, Rioux D, McDougall JJ. 2015. Mechanisms and Mediators That Drive Arthritis Pain. *Curr Osteoporos Rep* 13(4):216–224.
41. Ivanusic JJ. 2017. Molecular Mechanisms That Contribute to Bone Marrow Pain. *Front. Neurol.* 8:458.
42. Nencini S, Ivanusic J. 2017. Mechanically sensitive A δ nociceptors that innervate bone marrow respond to changes in intra-osseous pressure. *The Journal of Physiology* 595(13):4399–4415.
43. Nencini S, Ringuet M, Kim D-H, et al. 2017. Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain. *Mol Pain* 13:1744806917697011.
44. Nencini S, Ringuet M, Kim D-H, et al. 2018. GDNF, Neurturin, and Artemin Activate and Sensitize Bone Afferent Neurons and Contribute to Inflammatory Bone Pain. *J. Neurosci.* 38(21):4899–4911.
45. Philpott HT, O'Brien M, McDougall JJ. 2017. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. *Pain* 158(12):2442–2451.
46. Grubb BD. 2004. Activation of sensory neurons in the arthritic joint. *Novartis Found Symp* 260:28–36; discussion 36–48, 100–104, 277–279.
47. Sagar DR, Nwosu L, Walsh DA, Chapman V. 2015. Dissecting the contribution of knee joint NGF to spinal nociceptive sensitization in a model of OA pain in the rat. *Osteoarthritis and Cartilage* 23(6):906–913.
48. Miller RE, Malfait AM. 2017. Osteoarthritis pain: What are we learning from animal models? *Best Practice & Research Clinical Rheumatology* 31(5):676–687.
49. Bergman RF, Lammlin L, Junginger L, et al. 2023. Sexual dimorphism of the synovial transcriptome underpins greater PTOA disease severity in male mice following joint injury. *Osteo Cart* :S1063458423009159.
50. Eitner A, Pester J, Nietzsche S, et al. 2013. The innervation of synovium of human osteoarthritic joints in comparison with normal rat and sheep synovium. *Osteoarthritis and Cartilage* 21(9):1383–1391.

51. Obeidat AM, Miller RE, Miller RJ, Malfait A-M. 2019. The nociceptive innervation of the normal and osteoarthritic mouse knee. *Osteo Cart* 27(11):1669–1679.
52. Obeidat AM, Ishihara S, Li J, et al. 2024. Intra-articular sprouting of nociceptors accompanies progressive osteoarthritis: comparative evidence in four murine models. *Front Neuroanat* 18:1429124.
53. Aso K, Shahtaheri SM, McWilliams DF, Walsh DA. 2021. Association of subchondral bone marrow lesion localization with weight-bearing pain in people with knee osteoarthritis: data from the Osteoarthritis Initiative. *Arthritis Res Ther* 23(1):35.
54. Ivanusic J, Imlach W, Thai J, et al. 2025. Loss of peptidergic innervation of the subchondral bone in a murine model of MIA-induced osteoarthritis. *Osteoarthritis and Cartilage* 33(12):1419–1429.
55. Morgan M, Nazemian V, Harrington K, Ivanusic JJ. 2022. Mini review: The role of sensory innervation to subchondral bone in osteoarthritis pain. *Front. Endocrinol.* 13:1047943.
56. Suri S, Walsh DA. 2012. Osteochondral alterations in osteoarthritis. *Bone* 51(2):204–211.
57. Thai J, Fuller-Jackson J, Ivanusic JJ. 2024. Using tissue clearing and light sheet fluorescence microscopy for the three-dimensional analysis of sensory and sympathetic nerve endings that innervate bone and dental tissue of mice. *J of Comparative Neurology* 532(1):e25582.
58. Ko FC, Fullam S, Lee H, et al. 2025. Clearing-enabled light sheet microscopy as a novel method for three-dimensional mapping of the sensory innervation of the mouse knee. *Journal Orthopaedic Research* 43(3):632–639.
59. Chen P, Chai J, Soundararajan A, et al. 2026. Multiscale 3D Whole Joint Cellular and Molecular Mapping Reveals Disease-Specific Neurovascular Plasticity Underlying the Structure-Pain Relationship. *Advanced Science* 13(1):e11226.
60. Aso K, Shahtaheri SM, Hill R, et al. 2020. Contribution of nerves within osteochondral channels to osteoarthritis knee pain in humans and rats. *Osteo Cart* 28:1245–1254.
61. Raoof R, Martin Gil C, Lafeber FPJG, et al. 2021. Dorsal Root Ganglia Macrophages Maintain Osteoarthritis Pain. *J Neurosci* 41(39):8249–8261.
62. Martin Gil C, Raoof R, Versteeg S, et al. 2024. Myostatin and CXCL11 promote nervous tissue macrophages to maintain osteoarthritis pain. *Brain, Behavior, and Immunity* 116:203–215.
63. Geraghty T, Ishihara S, Obeidat AM, et al. 2024. Acute systemic macrophage depletion in osteoarthritic mice alleviates pain-related behaviors and does not affect joint damage. *Arthritis Res Ther* 26(1):224.
64. Tran PB, Miller RE, Ishihara S, et al. 2017. Spinal microglial activation in a murine surgical model of knee osteoarthritis. *Osteo Cart* 25(5):718–726.
65. Geraghty T, Obeidat AM, Ishihara S, et al. 2023. Age-Associated Changes in Knee Osteoarthritis, Pain-Related Behaviors, and Dorsal Root Ganglia Immunophenotyping of Male and Female Mice. *Arthritis Rheumatol* 75(10):1770–1780.
66. Chuluunbat O, Ikemoto H, Okumo T, et al. 2024. Electroacupuncture Inhibits Cartilage Degeneration in a Rat Knee Osteoarthritis (KOA) Model by Suppressing ADAMTS5 Expression. *Cureus* [cited 2026 Jan 12] Available from: <https://www.cureus.com/articles/312782-electroacupuncture-inhibits-cartilage-degeneration-in-a-rat-knee-osteoarthritis-koa-model-by-suppressing-adamts5-expression>.
67. Mousseau M, Burma NE, Lee KY, et al. 2018. Microglial pannexin-1 channel activation is a spinal determinant of joint pain. *Sci. Adv.* 4(8):eaas9846.

68. He BH, Christin M, Mouchbahani-Constance S, et al. 2017. Mechanosensitive ion channels in articular nociceptors drive mechanical allodynia in osteoarthritis. *Osteoarthritis and Cartilage* 25(12):2091–2099.
69. Orita S, Ishikawa T, Miyagi M, et al. 2012. Percutaneously absorbed NSAIDs attenuate local production of proinflammatory cytokines and suppress the expression of c-Fos in the spinal cord of a rodent model of knee osteoarthritis. *J Orthop Sci* 17(1):77–86.
70. de Sousa Valente J, Alawi KM, Keringer P, et al. 2020. Examining the role of transient receptor potential canonical 5 (TRPC5) in osteoarthritis. *Osteoarthr Cartil Open* 2(4):100119.
71. Kwon M, Kim T, Park EH, et al. 2025. Substance P-neurokinin 1 receptor signal involves the development of osteoarthritis-induced chronic pain in rats. *J Neuropathol Exp Neurol* 84(10):879–891.
72. Ogonna AC, Clark AK, Gentry C, et al. 2013. Pain-like behaviour and spinal changes in the monosodium iodoacetate model of osteoarthritis in C57Bl/6 mice. *Eur J Pain* 17(4):514–526.
73. Bird GC, Han JS, Fu Y, et al. 2006. Pain-related synaptic plasticity in spinal dorsal horn neurons: role of CGRP. *Mol Pain* 2:31.
74. Devonshire IM, Burston JJ, Xu L, et al. 2017. Manganese-enhanced magnetic resonance imaging depicts brain activity in models of acute and chronic pain: A new window to study experimental spontaneous pain? *NeuroImage* 157:500–510.
75. Lehtinen P, Stenroos P, Salo R, et al. 2026. Functional MRI following sensory stimulation in rat monosodium iodoacetate model of osteoarthritis pain as a tool for drug therapy discovery. *Neuroimage* 325:121670.
76. Griffith JL, Valdes-Hernandez PA, Yeater TD, et al. 2026. Post-traumatic osteoarthritis in aged rodents is associated with brain changes that correlate with joint remodeling. *J Pain* 39:105594.